Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-03-23 00:00:00 ET · period of report 2022-03-21 · accession 0001708138-22-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-23 | 2022-03-21 | REGN | Tessier-Lavigne Marc | Dir | M - OptEx | $380.95 | +7,439 | 9,708 | +328% | +$2.83M |
| D | 2022-03-23 | 2022-03-21 | REGN | Tessier-Lavigne Marc | Dir | S - Sale+OE | $690.00 | -7,439 | 2,269 | -77% | -$5.13M |
| D | 2022-03-23 | 2022-03-21 | REGN | Tessier-Lavigne Marc | Dir | M - OptEx | $0.00 | -7,439 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-21 | M | A | 7,439 | $380.95 | 9,708 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-21 | S | D | 7,439 | $690.00 | 2,269 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-21 | M | D | 7,439 | $0.00 | 0 | D | $380.95 · — to 2028-01-02 | 7,439 Common Stock | (F2) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |